Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SEMEX:BNTXN 54 EV-to-FCF is 11.43 as of Aug. 08, 2026, which is 1294% above its 10-year median of 0.82. GuruFocus rates MEX:BNTXN with a GF Score™ of 54/100 and a GF Value™ of MXN1,457.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 341 Biotechnology companies, BioNTech SE ranks better than 56.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioNTech SE's Enterprise Value is MXN112,778 Mil.
BioNTech SE's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN9,870 Mil. Therefore, BioNTech SE's EV-to-FCF for today is 11.43.
The historical rank and industry rank for BioNTech SE's EV-to-FCF or its related term are showing as below:
MEX:BNTXN'
s EV-to-FCF Range Over the Past 10 Years
Min: -264.96 Med: 0.82 Max: 74.92
Current: 11.76
During the past 10 years, the highest EV-to-FCF of BioNTech SE was 74.92. The lowest was -264.96. And the median was 0.82.
MEX:BNTXN's EV-to-FCF is ranked better than 56.01% of 341
companies
in the Biotechnology industry
Industry Median: 15.04
vs MEX:BNTXN: 11.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioNTech SE's PE Ratio (TTM) for today is calculated as:
BioNTech SE's share price for today is MXN1590.00.
BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-137.066.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioNTech SE EV-to-FCF Related Terms
BioNTech SE EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioNTech SE's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BNTXN vs INSM, INCY, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, BioNTech SE's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioNTech SE's EV-to-FCF falls into.
BioNTech SE's current Enterprise Value is MXN112,778 Mil.
BioNTech SE's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN9,870 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (MEX:BNTXN) has a EV-to-FCF of 11.43 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioNTech SE and its competitors. This is 1294% above median its historical median of 0.82. According to the industry distribution chart, BioNTech SE ranks #150 out of 341 companies in the Biotechnology industry, placing it in the top 44%.
Is BioNTech SE's EV-to-FCF too high?
BioNTech SE's current EV-to-FCF of 11.43 is 1294% above median its 10-year median of 0.82. The Biotechnology industry median EV-to-FCF is 15.04. BioNTech SE's value of 11.43 is 24% below this industry median. Based on the distribution chart, BioNTech SE ranks #150 out of 341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's EV-to-FCF compare to INSM and INCY?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #150 out of 341 companies for EV-to-FCF. This puts BioNTech SE in the upper half of its industry. The industry median EV-to-FCF is 15.04. BioNTech SE's value of 11.43 is 24% below this benchmark. While the company's 10-year median is 0.82 vs. the industry median of 15.04, BioNTech SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.04, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current EV-to-FCF of 11.43 is 24% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current EV-to-FCF is 11.43, which is 1294% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (MEX:BNTXN) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,457.90, compared to a current price of MXN1,590.00 — trading 9.1% above its estimated fair value. The current EV-to-FCF is 11.43, which is 1294% above median its 10-year median of 0.82 and 24% below the Biotechnology industry median of 15.04. BioNTech SE's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioNTech SE (MEX:BNTXN), the current EV-to-FCF is 11.43 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (MEX:BNTXN) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of MXN1,590.00 is trading 9.1% above its estimated GF Value™ of MXN1,457.90.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for MEX:BNTXN:
EV-to-FCF: 11.43 (1294% above median its 10-year median of 0.82)
GF Value™: MXN1,457.90 vs. price of MXN1,590.00 (9.1% above fair value)
Industry Position: 24% below the Biotechnology median (#150 of 341)
No single metric tells the full story. See the MEX:BNTXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
54GF Score
Get the complete analysis for MEX:BNTXN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNTXN has been successfully added to your 
